- |||||||||| #WPD2023 Parkinson’s Disease Emerging therapies such as CB101, Neural microtissues, NBTX 001, MEDI1341, Lu AF28996, KDT 3594, Prasinezumab, P2B001, DNL 151, Tavapadon are expected to have a significant impact on the PD market in the coming years @Medgadget https://t.co/huWF94ybh0 (Twitter) - Apr 10, 2023
- |||||||||| AM006 / Kissei, AffaMed Therap
Trial completion, Trial completion date, Trial primary completion date: A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. (clinicaltrials.gov) - Feb 17, 2021 P2, N=74, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Feb 2020 | Trial primary completion date: Jun 2020 --> Feb 2020
- |||||||||| AM006 / Kissei, AffaMed Therap
Enrollment closed: A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. (clinicaltrials.gov) - Mar 30, 2020 P2, N=100, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Feb 2020 | Trial primary completion date: Jun 2020 --> Feb 2020 Recruiting --> Active, not recruiting
- |||||||||| AM006 / Kissei, AffaMed Therap
Enrollment closed, Trial primary completion date: Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease (clinicaltrials.gov) - Dec 7, 2018 P1, N=36, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Aug 2018 | Trial primary completion date: Jan 2019 --> Aug 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Jan 2019
|